Antibody-drug conjugates represent one of the most promising and rapidly advancing classes of cancer therapeutics, combining the targeting precision of monoclonal antibodies with the potent cytotoxic activity of small molecule drugs. Azintuxizumab vedotin is an investigational antibody-drug conjugate that targets CD70, a transmembrane protein expressed on the surface of various hematologic malignancies and solid tumors. The construct consists of a fully human monoclonal antibody specific for CD70 conjugated to the potent anti-mitotic agent monomethyl auristatin E via a protease-cleavable valine-citrulline linker. This linker-payload combination represents the same technology used in several approved antibody-drug conjugates, providing a well-characterized and clinically validated platform.The successful development of Azintuxizumab vedotin and other antibody-drug conjugates depends critically on robust bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic monitoring. Unlike conventional monoclonal antibodies, antibody-drug conjugates present unique bioanalytical challenges because the analyte exists in multiple forms including total antibody, conjugated antibody, and free payload. Accurate quantification of the intact conjugate is essential for understanding the relationship between exposure and response, optimizing dosing regimens, and ensuring patient safety.
Figure 1. Azintuxizumab Vedotin ADC ELISA Kit for Antibody-Drug Conjugate Monitoring.
CD70 is a type II transmembrane protein belonging to the tumor necrosis factor superfamily. It is the ligand for CD27, a costimulatory receptor expressed on T cells, natural killer cells, and B cells. The interaction between CD70 and CD27 plays an important role in immune regulation, providing costimulatory signals that promote T cell activation, proliferation, and survival. Under normal physiological conditions, CD70 expression is tightly regulated and transient, occurring primarily on activated lymphocytes and dendritic cells. In cancer, CD70 expression becomes dysregulated, with many tumor types exhibiting constitutive high-level surface expression of CD70. This aberrant expression is often associated with poor prognosis, increased metastatic potential, and immune evasion. The mechanisms driving CD70 overexpression in cancer include genetic alterations, epigenetic changes, and activation of oncogenic signaling pathways.
Several features make CD70 an attractive target for antibody-based cancer therapy. First, CD70 expression in normal tissues is highly restricted, limiting the potential for on-target off-tumor toxicity. Second, CD70 is expressed on the surface of a wide range of hematologic and solid malignancies, providing broad therapeutic applicability. Third, CD70 rapidly internalizes upon antibody binding, a critical property for antibody-drug conjugate approaches that require efficient intracellular delivery of cytotoxic payloads. Fourth, CD70 is expressed on cancer stem cells in some tumor types, suggesting that CD70 targeting may eliminate the cells responsible for tumor initiation and relapse.
| Technology | Details |
| Antibody Component | The antibody component of Azintuxizumab vedotin is a fully human immunoglobulin gamma one monoclonal antibody with high affinity and specificity for human CD70. The antibody binds to CD70 with sub-nanomolar affinity and exhibits rapid internalization upon target engagement. The fully human nature of the antibody is expected to reduce the immunogenicity potential compared to chimeric or humanized antibodies, potentially improving safety and tolerability. |
| Linker Technology | Azintuxizumab vedotin employs a valine-citrulline dipeptide linker that is specifically cleaved by cathepsin proteases within the lysosomal compartment. This linker design provides several advantages. The valine-citrulline linker is stable in circulation, preventing premature release of the payload and minimizing systemic toxicity. The linker is efficiently cleaved by cathepsins following internalization and lysosomal trafficking, enabling targeted payload release within the tumor cell. The linker also incorporates a self-immolative spacer that facilitates complete release of unmodified monomethyl auristatin E following proteolytic cleavage. |
| Payload Mechanism | Monomethyl auristatin E is a synthetic analog of the natural marine toxin dolastatin ten. This potent anti-mitotic agent binds to tubulin with high affinity, competing with the vinca alkaloid binding site. Monomethyl auristatin E inhibits microtubule polymerization, preventing formation of the mitotic spindle. Cells exposed to monomethyl auristatin E accumulate in the G2/M phase of the cell cycle and subsequently undergo apoptotic cell death. The potency of monomethyl auristatin E is extremely high, with half-maximal inhibitory concentrations in the sub-nanomolar range for many cancer cell lines. |
Quantification of antibody-drug conjugates presents unique challenges compared to conventional monoclonal antibodies. Unlike standard antibodies, antibody-drug conjugates are heterogeneous mixtures with variable drug-to-antibody ratios. The intact conjugate may undergo deconjugation in circulation or during sample handling, releasing free payload. Additionally, the conjugate may be recognized by pre-existing or treatment-emergent anti-drug antibodies that can interfere with accurate quantification.
For pharmacokinetic characterization of antibody-drug conjugates, measurement of the intact conjugate is critical. The intact conjugate represents the pharmacologically active species capable of delivering the payload to target cells. Concentrations of intact conjugate in circulation determine the amount of payload that can potentially be delivered to the tumor. Accurate quantification of intact conjugate enables calculation of key pharmacokinetic parameters including clearance, half-life, and exposure.
Regulatory agencies require comprehensive bioanalytical characterization of antibody-drug conjugates including measurement of total antibody, intact conjugate, and free payload. Validated methods must be used to support clinical development and regulatory submissions. The Azintuxizumab Vedotin ADC ELISA Kit is designed to meet these expectations, providing a validated platform for intact conjugate quantification.
The Azintuxizumab Vedotin ADC ELISA Kit is designed for the quantitative determination of intact Azintuxizumab vedotin antibody-drug conjugate concentrations in human serum, plasma, or other biological matrices. This kit is optimized for pharmacokinetic studies and therapeutic monitoring applications in clinical research and regulatory-compliant environments.
| Sample Collection and Handling | Assay Optimization | Data Interpretation |
| Collect blood using standard venipuncture techniques. Serum separator tubes are recommended for serum collection. For plasma collection, tubes containing EDTA, heparin, or citrate are acceptable. Samples should be processed within a few hours after collection. Serum or plasma should be separated by centrifugation and stored at low temperatures. | Run duplicate wells for each sample to improve precision. Include a full standard curve on each plate. Use the provided controls to validate plate performance before interpreting results. Pre-dilute high-concentration samples to bring them within the linear range of the standard curve. Follow the recommended incubation times and temperatures precisely. | Interpolate concentrations from the standard curve using appropriate regression methods such as four-parameter logistic curve fitting. Quality control samples must meet acceptance criteria for the run to be considered valid. Samples with concentrations above the highest standard should be diluted and reassayed. Samples with concentrations below the lower limit of quantification should be reported as below the limit of quantification. |
Azintuxizumab vedotin represents an innovative approach to targeted cancer therapy, combining the specificity of CD70 targeting with the potency of monomethyl auristatin E payload delivery. The antibody-drug conjugate format enables selective killing of CD70 expressing tumor cells while sparing normal tissues, potentially improving the therapeutic index compared to conventional chemotherapy. The successful development of Azintuxizumab vedotin depends on reliable bioanalytical methods to support pharmacokinetic characterization and therapeutic monitoring. The Azintuxizumab Vedotin ADC ELISA Kit provides a validated, sensitive, and specific solution for quantifying intact conjugate concentrations in biological matrices. The dual recognition format ensures detection of fully functional conjugate while avoiding interference from deconjugated antibody or free payload. Key performance characteristics including high sensitivity, wide dynamic range, and excellent reproducibility support use in preclinical studies, clinical trials, and potential future clinical applications. As antibody-drug conjugates continue to transform cancer treatment, reliable ELISA-based methods for intact conjugate quantification will remain essential for optimizing the use of these innovative therapeutics.
| Cat. No. | Product Name | Detection Method | |
| DEIA-JY25419 | Azintuxizumab vedotin (ADC) ELISA Kit | sELISA | Inquiry |
